OverviewSuggest Edit

TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the Company is developing two therapies targeting hematological malignancies: TG-1101 (ublituximab) is a novel, glycoengineered, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes and TGR-1202, an orally available Phosphoinositide 3-kinase delta inhibitor.

TypePublic
Founded1993
HQNew York, NY, US
Websitetgtherapeutics.com
Overall CultureD-

Latest Updates

Employees (est.) (May 2020)153(+15%)
Revenue (FY, 2019)$152 K
Share Price (Jan 2021)$50.2 (+2%)
Cybersecurity ratingBMore

Key People/Management at TG Therapeutics

Michael S. Weiss

Michael S. Weiss

Executive Chairman, President and Chief Executive Officer
Sean A. Power

Sean A. Power

Chief Financial Officer
Adam Waldman

Adam Waldman

Chief Commercialization Officer
Owen A. O'Connor

Owen A. O'Connor

Chief Scientific Officer
Show more

TG Therapeutics Office Locations

TG Therapeutics has an office in New York
New York, NY, US (HQ)
2 Gansevoort St 9th Floor
Show all (1)

TG Therapeutics Financials and Metrics

TG Therapeutics Revenue

TG Therapeutics's revenue was reported to be $152 k in FY, 2019
USD

Revenue (Q2, 2020)

38.0k

Net income (Q2, 2020)

(52.9m)

EBIT (Q2, 2020)

(50.8m)

Market capitalization (19-Jan-2021)

6.9b

Closing stock price (19-Jan-2021)

50.2

Cash (30-Jun-2020)

260.5m

EV

6.7b
TG Therapeutics's current market capitalization is $6.9 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

19.0k152.4k152.4k152.4k152.4k152.4k152.0k152.0k

Revenue growth, %

General and administrative expense

554.7k4.8m16.3m15.2m15.0m

R&D expense

327.3k21.0m13.7m40.1m47.7m69.2m102.5m159.4m154.2m
USDQ2, 2011

Financial Leverage

-8.5 x
Show all financial metrics

TG Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

TG Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

TG Therapeutics Online and Social Media Presence

Embed Graph

TG Therapeutics Company Culture

  • Overall Culture

    D-

    52/100

  • CEO Rating

    B

    76/100

  • Compensation

    D+

    61/100

Learn more on Comparably

TG Therapeutics News and Updates

TG Therapeutics to Participate in the B. Riley Securities Oncology Investor Conference

Fireside chat scheduled for Wednesday, January 20, 2021 at 10:00 AM ET Fireside chat scheduled for Wednesday, January 20, 2021 at 10:00 AM ET

TG Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Presentation scheduled for Tuesday, January 12, 2021 at 2:00 PM ET Presentation scheduled for Tuesday, January 12, 2021 at 2:00 PM ET

Thinking about trading options or stock in Moderna, Alibaba, TG Therapeutics, Tesla, or American Airlines?

NEW YORK, Dec. 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, BABA, TGTX, TSLA, and AAL. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis

Both studies met their primary endpoint of significantly reducing annualized relapse rate (ARR) (p<0.005 in each study) with ublituximab demonstrating an ARR of <0.10 in each of the studies

TG Therapeutics Announces Triple Combination Data Presentations at the at the 62nd American Society of Hematology Annual Meeting

U2 + Venetoclax: 100% ORR at cycle 12 (n=27), including 41% CR rate, and 96% of patients achieving undetectable MRD in the peripheral blood and 77% achieving undetectable MRD in bone marrow

TG Therapeutics Recaps Schedule of Data Presentations at the Upcoming 62nd American Society of Hematology Annual Meeting and Exposition

NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today recapped the schedule of data presentations at the upcoming 62nd American Society of Hematology (ASH) annual meeting and exposition, to be held virtually December 5 – 8, 2020.
Show more

TG Therapeutics Blogs

TG Therapeutics Announces Pivotal Data from the UNITY-CLL and UNITY-NHL Clinical Trials Presented at the 62nd American Society of Hematology Annual Meeting

UNITY-CLL: U2 significantly improved progression-free survival over obin utuz u mab   plus chlorambucil (HR= 0 .54, p

TG Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results

NEW YORK , Nov. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2020 and recent company developments. Michael S. Weiss , the Company's Executive Chairman and Chief Executive Officer, stated, “This has

TG Therapeutics Announces Data Presentations at the Upcoming 62nd American Society of Hematology Annual Meeting and Exposition

TG Therapeutics Announces Data Presentations at the Upcoming 62nd American Society of Hematology Annual Meeting and Exposition Content Import Mon, 11/02/2020 - 07:02 TG Therapeutics Announces Data Presentations at the Upcoming 62nd American Society of Hematology Annual Meeting and Expositi…

TG Therapeutics Announces Fast Track Designation Granted by the FDA to Ublituximab in Combination with Umbralisib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia

TG Therapeutics Announces Fast Track Designation Granted by the FDA to Ublituximab in Combination with Umbralisib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia Content Import Wed, 10/21/2020 - 07:31 TG Therapeutics Announces Fast Track Designation Granted by the FDA…

TG Therapeutics Announces FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma and Follicular Lymphoma

NEW YORK , Aug. 13, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics , Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for umbralisib, the Company’s investigational once-daily, oral, dual inhibitor of PI3K-delta and

TG Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results

NEW YORK , Aug. 10, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2020 and recent company developments. Michael S. Weiss , the Company's Executive Chairman and Chief Executive Officer, stated, “We are
Show more

TG Therapeutics Frequently Asked Questions

  • When was TG Therapeutics founded?

    TG Therapeutics was founded in 1993.

  • Who are TG Therapeutics key executives?

    TG Therapeutics's key executives are Michael S. Weiss, Sean A. Power and Adam Waldman.

  • How many employees does TG Therapeutics have?

    TG Therapeutics has 153 employees.

  • What is TG Therapeutics revenue?

    Latest TG Therapeutics annual revenue is $152 k.

  • What is TG Therapeutics revenue per employee?

    Latest TG Therapeutics revenue per employee is $993 .

  • Who are TG Therapeutics competitors?

    Competitors of TG Therapeutics include Biogen, MyoKardia and Athersys.

  • Where is TG Therapeutics headquarters?

    TG Therapeutics headquarters is located at 2 Gansevoort St 9th Floor, New York.

  • Where are TG Therapeutics offices?

    TG Therapeutics has an office in New York.

  • How many offices does TG Therapeutics have?

    TG Therapeutics has 1 office.